🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
To evaluate if hyper-fractionated TBI or TMLI followed by Treg/Tcon adoptiv...
Status
Unknown
Location
University of Perugia
Start Date
2014-02
Trial ID
NCT03977103
Treatments Being Tested
RATIONALE: Giving chemotherapy drugs, such as fludarabine and cyclophospham...
Status
Completed
Location
Masonic Cancer Center at University of Minnesota
Start Date
2005-07-28
Trial ID
NCT00309842
RATIONALE: Photopheresis treats the patient's blood with drugs and ultravio...
Status
Completed
Location
Mayo Clinic Scottsdale
Start Date
2006-10-24
Trial ID
NCT00045305
Background: CGD causes infections and inflammation. The only cure currentl...
Status
Active Not Recruiting
Location
National Institutes of Health Clinical Center
Start Date
2019-10-28
Trial ID
NCT03910452
The purpose of this study is to determine whether a repeat dose administrat...
Status
Completed
Location
Algemeen Ziekenhuis Sint-Jan
Start Date
2015-10-09
Trial ID
NCT02500550
Treatments Being Tested
The purpose of this study is to find out if getting a blood stem cell trans...
Status
Completed
Location
Memorial Sloan Kettering Cancer Center
Start Date
2012-05-05
Trial ID
NCT01596257
Treatments Being Tested
The purpose of this study is to determine the safety and toxicity and feasi...
Status
Terminated
Location
Columbia Presbyterian Medical Center
Start Date
2007-09-06
Trial ID
NCT00801931
This is an open-label phase 1 safety and feasibility study that will employ...
Status
Recruiting
Location
Children's National Hospital
Start Date
2024-09-20
Trial ID
NCT06193759
To evaluate whether palifermin (rHuKGF) administered as a single dose is no...
Status
Completed
Location
Multiple Locations
Start Date
2005-01
Trial ID
NCT00109031
Treatments Being Tested
Determination of the maximum tolerated dose (MTD) of fractionated RIT with ...
Status
Withdrawn
Location
Multiple Locations
Start Date
TBD
Trial ID
NCT02577094